Company intelligence / Profile preview
Delcath
Queensbury, New York, United Statesdelcath.com ↗
- Ownership
- Public · DCTH
- Development stage
- Other
01
Overview
Delcath's HEPZATO KIT (melphalan/Hepatic Delivery System) is FDA approved and has demonstrated clinically meaningful tumor shrinkage with reduced systemic toxicity in metastatic uveal melanoma. Ongoing trials target other liver-dominant cancers, including metastatic breast and colorectal cancer. The pivotal FOCUS Phase 3 trial provided the efficacy basis for FDA approval[3][4].
- Therapeutic areas
- Oncology
- Modalities
- DeviceSmall molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Synerx Pharma, LLC (melphalan supply)Mylan Teoranta (melphalan supply)
04
Financials
- Market cap
- $502.8M
- Total revenue
- $85.2M
- Enterprise value
- $409.3M
Beyond the preview
Go deeper on Delcath.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Delcath.